SCHEMBL370852

SCHEMBL370852

Cc1cc2[nH]ncc2c2nc(Nc3ccccn3)sc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 5/20 0.47
KDR P35968 5/20 0.47
KCNH2 Q12809 3/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
MAPK10 P53779 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
TRPV4 Q9HBA0 1/20 0.44
CDK2 P24941 2/20 0.44
CCNE1 P24864 1/20 0.44
CDK3 Q00526 1/20 0.44
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 1/20 0.41
USP2 O75604 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359265 0.67 GRM4 (0.43) GRM4KDRKCNH2ALDH1A1LMNA
SCHEMBL370521 0.66 GRM4 (0.48) GRM4KDRKCNH2ALDH1A1LMNA
SCHEMBL13701559 0.65 KDR (1.00) GRM4KDRALDH1A1LMNAMAPK10
SCHEMBL369152 0.64 GRM4 (1.00) GRM4KDRKCNH2ALDH1A1LMNA
SCHEMBL10670650 0.64 NPC1 (0.57) GRM4KDRALDH1A1LMNAMAPK10
SCHEMBL8738378 0.64 ALDH1A1 (0.97) KDRALDH1A1LMNAMAPK10RXFP1
SCHEMBL925127 0.64 NPC1 (0.56) GRM4KDRALDH1A1LMNAMAPK10
SCHEMBL366546 0.63 GRM4 (1.00) GRM4KCNH2
SCHEMBL30745793 0.63 GRM4 (0.63) GRM4KDRKCNH2ALDH1A1LMNA
SCHEMBL5174932 0.63 GRM4 (0.63) GRM4KDRKCNH2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US claimed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP claimed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO claimed
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 GRM4 1/4885KDR 2474/4885KCNH2 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.